Pegylated Interferon α in Previously Interferon-treated CHB(Leading Study)

NARecruitingINTERVENTIONAL
Enrollment

2,016

Participants

Timeline

Start Date

February 4, 2024

Primary Completion Date

February 28, 2027

Study Completion Date

August 31, 2027

Conditions
Chronic Hepatitis b
Interventions
DRUG

Peginterferon α-2b based treatment group

Peginterferon α-2b injection, 180mcg, s.c, once a week, for 48 weeks. If the baseline HBV DNA is higher than the minimum detection limit (using high-sensitivity kit), combined with nucleos(t)ide analogs (NAs) is recommended.

DRUG

NAs monotherapy group

First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally, for 48 weeks.

Trial Locations (1)

Unknown

RECRUITING

Department of Infectious Diseases , Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Qing XIe

OTHER